NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIAID E-076-2015-4-BR-04 METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION BR National Stage 112017003891-9 Pending
NCI E-174-2011-0-JP-18 Pseudomonas Exotoxin A With Less Immunogenic T Cell And/Or B Cell Epitopes JP DIV 2017-031283 Issued
NCI E-750-2013-0-HK-10 Methods for Subtyping Lymphoma Types by Means of Expression Profiling HK National Stage 17101847.4 Issued
NICHD E-016-2013-2-US-05 Assay To Measure Midkine or Pleiotrophin Level for Diagnosing a Growth US DIV 15/435,880 9658233 Issued PDF
NCI E-291-2014-0-KR-08 Method For Purifying Antibody Using PBS KR National Stage 10-2017-7004441 Pending
NCI E-136-2018-1-PL-24 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab PL EP 17753704.0 Issued
NCI E-136-2018-1-SE-25 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab SE EP 17753704.0 Issued
NCI E-136-2018-1-NO-23 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab NO EP 17753704.0 Issued
NCI E-136-2018-1-CZ-15 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab CZ EP 17753704.0 Issued
NCI E-136-2018-1-DK-17 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab DK EP 17753704.0 Issued
NCI E-136-2018-1-EP-05 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab EP National Stage 17753704.0 Issued
NCI E-136-2018-1-TR-26 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab TR EP 17753704.0 Issued
NCI E-136-2018-1-CH-14 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab CH EP 17753704.0 Issued
NCI E-136-2018-1-GR-18 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab GR EP 17753704.0 Issued
NCI E-136-2018-1-HU-19 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab HU EP 17753704.0 Issued
NCI E-136-2018-1-IE-20 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab IE EP 17753704.0 Issued
NCI E-136-2018-1-IT-21 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab IT EP 17753704.0 Issued
NCI E-136-2018-1-BE-13 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab BE EP 17753704.0 Issued
NCI E-136-2018-1-AT-12 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab AT EP 17753704.0 Issued
NCI E-136-2018-1-NL-22 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab NL EP 17753704.0 Issued
NCI E-136-2018-1-MA-08 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab MA EP 17753704.0 Issued
NCI E-136-2018-1-DE-16 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab DE EP 17753704.0 Issued
NCI E-136-2018-1-PCT-01 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab PCT PCT PCT/US2017/017804 Expired
NCI E-136-2018-1-RU-10 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab RU National Stage 2018131377 Pending
NCI E-136-2018-1-KR-07 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab KR National Stage 2018-7024215 Pending
NCI E-136-2018-1-CN-04 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab CN National Stage 201780011505 Pending
NCI E-136-2018-1-CA-03 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab CA National Stage 3014674 Pending
NCI E-136-2018-1-JP-06 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab JP National Stage 2021-064539 Pending
NCI E-136-2018-1-MX-09 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab MX National Stage 2018009867 Pending
NCI E-136-2018-1-AU-02 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab AU National Stage 2017221268 Pending
NCI E-078-2016-0-PCT-02 RNA/DNA HYBRID NANOPARTICLES MODIFIED WITH SINGLE STRANDED RNA TOEHOLDS AND USES THEREOF PCT PCT PCT/US2017/017661 Expired
NHLBI E-249-2006-3-PCT-02 Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure And Coronary Artery And Myocardial Protection Device PCT PCT PCT/US2017/017367 Expired
NCI E-051-2016-0-PCT-02 Method of Sensitizing Cancer Cells to the Cytoxic Effects of Apoptosis Inducing Ligands in Cancer Treatment PCT PCT PCT/US2017/017220 Expired
NIAID E-230-2015-0-PCT-02 RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE PCT PCT PCT/US2017/017038 Expired
NEI E-192-2014-1-EP-05 Surgical Tool and Method for Ocular Tissue Transplantation EP National Stage 15741462.4 Issued
NCI E-101-2016-0-CN-03 GENE SIGNATURE PREDICTIVE OF HEPATOCELLULAR CARCINOMA RESPONSE TO TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) CN National Stage 201780018693.9 Issued
NCI E-101-2016-0-PCT-02 GENE SIGNATURE PREDICTIVE OF HEPATOCELLULAR CARCINOMA RESPONSE TO TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) PCT PCT PCT/US2017/016851 Expired
NCI E-101-2016-0-EP-04 GENE SIGNATURE PREDICTIVE OF HEPATOCELLULAR CARCINOMA RESPONSE TO TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) EP National Stage 17706618.0 Pending
NCI E-234-2014-1-EP-13 METHODS FOR PRODUCING AUTOLOGOUS T CELLS USEFUL TO TREAT B CELL MALIGNANCIES AND OTHER CANCERS AND COMPOSITIONS THEREOF EP DIV 17154769.8 Abandoned
NIDDK E-742-2013-0-HK-06 A3 Adenosine Receptor Agonists HK National Stage 17101156.9 Issued
NCI E-080-2008-0-US-06 Human Monoclonal Antibodies Specific for CD22 US CON 15/424,238 10494435 Issued PDF
NCI E-141-2008-0-US-32 Complexes Of IL-15 And IL-15R AIpha And Uses Thereof US CON 15/424,621 10265382 Issued PDF
NCI E-093-2016-0-PCT-02 Inducible Arginase PCT PCT PCT/US2017/016484 Abandoned
NIAID E-214-2015-0-US-09 Conformationally Stabilized RSV Pre-Fusion F Proteins US CON 15/424,107 Pending
NIDDK E-011-2014-0-HK-12 Piperidine and Piperazine Derivatives and Their Use in Treating Viral Infections and Cancer HK National Stage 171011550.0 Abandoned
NCI E-056-2011-0-AU-44 The Development And Use Of A Recombinant Brachyury Saccharomyces Cerevisiae (yeast) Vaccine For The Prevention And/or Therapy Of Human Cancer AU DIV 2017200715 Issued
NIAID E-257-2015-0-PCT-02 COMPOUNDS FOR MODULATING FC-epsilon-RI-beta EXPRESSION AND USES THEREOF PCT PCT PCT/US2017/016042 Expired
NCI E-066-2016-0-PCT-02 FULVESTRANT FOR INDUCING IMMUNE-MEDIATED CYTOTOXIC LYSIS
OF CANCER CELLS 		PCT PCT PCT/US17/015829 Expired
NCI E-205-2010-2-JP-10 Photosensitizing Antibody-Flurophore Conjugates JP DIV 2017-13985 Pending
NCI E-174-2011-0-AU-16 Pseudomonas Exotoxin A With Less Immunogenic T Cell And/Or B Cell Epitopes AU DIV 2017200541 Issued